Stifel Maintains Buy on IGM Biosciences, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey has maintained a Buy rating on IGM Biosciences (NASDAQ:IGMS) but has reduced the price target from $26 to $25.

November 14, 2023 | 6:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on IGM Biosciences but lowers the price target from $26 to $25.
The reduction in price target by Stifel could have a mixed impact on IGMS stock. While the Buy rating reaffirms confidence in the company's prospects, the lowered price target may suggest a more conservative outlook on the stock's valuation, which could lead to short-term price volatility.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100